In our study, the inhibition of p-AKT expression and a decrease in PIP3 levels occurred in cisplatin-resistant lung cancer treated with Z-ligustilide+cisplatin; however, the knockdown of PLPP1 reversed the effects. The gene discussed is PLPP1; the disease is lung cancer.